FDA approves new dosing regimen for cetuximab


7 April 2021 - On 6 April 2021, the FDA approved a new dosage regimen of 500 mg/m2 as a 120 minute intravenous infusion every two weeks for cetuximab (Erbitux, ImClone) for patients with K-Ras wild type, EGFR-expressing colorectal cancer or squamous cell carcinoma of the head and neck.

This approval provides for a biweekly dosage regimen option in addition to the previously approved weekly dosage regimen for the approved indications when cetuximab is used as a single agent or in combination with chemotherapy.

Read FDA News

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Cancer , Outcome , Medicine , US